Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AGTR2 | P50052 | Type-2 angiotensin II receptor (Angiotensin II type-2 receptor) (AT2 receptor) | 7 | HypertensionNeuropathySecondary hypertension | Clinical-translation mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| AMGO1 | Q86WK6 | Amphoterin-induced protein 1 (AMIGO-1) (Alivin-2) | Predicted membrane proteinsTransporters | 1 | Adhesion and uptake mediationFusion and delivery mediation | 1 | 0.25 | |||
| AMPE | Q07075 | Glutamyl aminopeptidase (EAP) (EC 3.4.11.7) (Aminopeptidase A) (AP-A) (Differentiation antigen gp160) (CD antigen CD249) | CD markersEnzymesPlasma proteins | 1 | Hypertension | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | ||
| ANO5 | Q75V66 | Anoctamin-5 (Gnathodiaphyseal dysplasia 1 protein) (Transmembrane protein 16E) | Disease related genesHuman disease related genesPotential drug targets | 8 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| ANPRC | P17342 | Atrial natriuretic peptide receptor 3 (Atrial natriuretic peptide clearance receptor) (Atrial natriuretic peptide receptor type C) (ANP-C) (ANPR-C) (NPR-C) | Disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Heart failure | Clinical-translation mediationImmune mediationMetabolism mediation | 1 | 0.25 | ||
| APCD1 | Q8J025 | Protein APCDD1 (Adenomatosis polyposis coli down-regulated 1 protein) | 1 | Receptor-signaling mediation | 1 | 0.25 | ||||
| AT1A3 | P13637 | Sodium/potassium-transporting ATPase subunit alpha-3 (Na(+)/K(+) ATPase alpha-3 subunit) (EC 7.2.2.13) (Na(+)/K(+) ATPase alpha(III) subunit) (Sodium pump subunit alpha-3) | Disease related genesEnzymesHuman disease related genes | 10 | Clinical-translation mediationFusion and delivery mediation | 1 | 0.25 | |||
| AT1B1 | P05026 | Sodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependent ATPase subunit beta-1) | Metabolic proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| ATRN | O75882 | Attractin (DPPT-L) (Mahogany homolog) | Plasma proteinsPredicted membrane proteinsPredicted secreted proteins | 1 | Other mediation | 1 | 0.25 | |||
| AVR2B | Q13705 | Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB) | Cancer-related genesDisease related genesEnzymes | 1 | Nervous system paraneoplastic/autoimmune disorder | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| BTLA | Q7Z6A9 | B- and T-lymphocyte attenuator (B- and T-lymphocyte-associated protein) (CD antigen CD272) | CD markersPredicted membrane proteinsPredicted secreted proteins | 1 | Lupus erythematosusSjogren syndromeSolid tumour/cancer | Clinical-translation mediationImmune mediation | 1 | 0.25 | ||
| CA2D1 | P54289 | Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1] | FDA approved drug targetsPlasma proteinsPredicted intracellular proteins | 1 | Anxiety disorderCardiovascular diseaseChronic obstructive pulmonary disease | Clinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| CAD10 | Q9Y6N8 | Cadherin-10 (T2-cadherin) | Predicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 | |||
| CAD19 | Q9H159 | Cadherin-19 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 | |||
| CADH9 | Q9ULB4 | Cadherin-9 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 | |||
| CAH12 | O43570 | Carbonic anhydrase 12 (EC 4.2.1.1) (Carbonate dehydratase XII) (Carbonic anhydrase XII) (CA-XII) (Tumor antigen HOM-RCC-3.1.3) | Disease related genesEnzymesFDA approved drug targets | 1 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | |||
| CANT1 | Q8WVQ1 | Soluble calcium-activated nucleotidase 1 (SCAN-1) (EC 3.6.1.6) (Apyrase homolog) (Putative MAPK-activating protein PM09) (Putative NF-kappa-B-activating protein 107) | Cancer-related genesDisease related genesEnzymes | 1 | Immune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| CCG8 | Q8WXS5 | Voltage-dependent calcium channel gamma-8 subunit (Neuronal voltage-gated calcium channel gamma-8 subunit) (Transmembrane AMPAR regulatory protein gamma-8) (TARP gamma-8) | 5 | Fusion and delivery mediation | 1 | 0.25 | ||||
| CCR7 | P32248 | C-C chemokine receptor type 7 (C-C CKR-7) (CC-CKR-7) (CCR-7) (BLR2) (CDw197) (Epstein-Barr virus-induced G-protein coupled receptor 1) (EBI1) (EBV-induced G-protein coupled receptor 1) (MIP-3 beta receptor) (CD antigen CD197) | Cancer-related genesCD markersG-protein coupled receptors | 7 | Malignant haematopoietic neoplasmMature B-cell leukaemia | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| CD151 | P48509 | CD151 antigen (GP27) (Membrane glycoprotein SFA-1) (Platelet-endothelial tetraspan antigen 3) (PETA-3) (Tetraspanin-24) (Tspan-24) (CD antigen CD151) | Blood group antigen proteinsCD markersDisease related genes | 4 | Adhesion and uptake mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| CD166 | Q13740 | CD166 antigen (Activated leukocyte cell adhesion molecule) (CD antigen CD166) | Cancer-related genesCD markersPlasma proteins | 1 | Solid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| CD1B | P29016 | T-cell surface glycoprotein CD1b (CD antigen CD1b) | CD markersPredicted membrane proteins | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| CD1C | P29017 | T-cell surface glycoprotein CD1c (CD antigen CD1c) | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.25 | ||||
| CD302 | Q8IX05 | CD302 antigen (C-type lectin BIMLEC) (C-type lectin domain family 13 member A) (DEC205-associated C-type lectin 1) (Type I transmembrane C-type lectin receptor DCL-1) (CD antigen CD302) | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.25 | ||||
| CD69 | Q07108 | Early activation antigen CD69 (Activation inducer molecule) (AIM) (BL-AC/P26) (C-type lectin domain family 2 member C) (EA1) (Early T-cell activation antigen p60) (GP32/28) (Leukocyte surface antigen Leu-23) (MLR-3) (CD antigen CD69) | CD markersPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 1 | 0.25 |